The FDA granted emergency use authorization June 12 to healthcare tech company Cue Heath's rapid COVID-19 test.
The single-use molecular test identifies the RNA of the virus that causes COVID-19 from a nasal swab sample in 25 minutes. The analysis is conducted at the point of care and results are transmitted to Cue's health app.
The FDA presently allows the tests to take place only under the supervision of licensed medical staff, but Cue is working toward receiving authorization for use in schools, workplaces and homes.